Dear Friends and Investors:
Please join us for a Private Investor presentation and dinner in Tysons Corner, VA on Thursday, September 28 at 5:30pm EDT featuring Coagulation Sciences, an amazing company that has developed technology to decrease unnecessary blood transfusions, which harm patients and are costly to hospitals.
This is for ACCREDITED INVESTORS with the ability to invest $100,000 and Investment Advisors ONLY
We welcome you to review the information below prior to the Company’s presentation.
About Coagulation Sciences:
Problem: Blood transfusions are associated with multiple complications including lung injury, fluid overload, kidney injury, immune system damage, and even shortened lifespan. Furthermore, at least 40% of transfusions are unnecessary, and hospitals lose as much as $800 per transfusion as reimbursement does not cover costs to transfuse. Most tests used to guide transfusion decisions were developed or are similar to tests developed in the 1940s and 1950s. Some require hours to days to return results. There needs to be improvement even beyond newer systems that return results more rapidly and can confirm a bleeding disorder, because they often provide insufficient information to correct the disorder.
Solution: Coagulation Sciences’ Multiple Coagulation Test System (MCTS) is a Point-of-Care platform that provides information reported by no existing test platform. The MCTS compares the ability of multiple therapies to correct bleeding disorders. Testing is fully automated and results are reported in ~ 10 minutes at the patient’s bedside.
Company: CS is a medical device company formed to solve the problem of inadequate testing that results in unnecessary transfusions, which are harmful to patients and costly to hospitals.
Team: The Team and Scientific and Business Advisors have many years of experience and knowledge in Patient Blood Management, Engineering and Technology Development, Business Development and Entrepreneurship, including several successful exits.
Markets: The Coagulation Analyzer market is projected to reach $5B by 2025 while the Point-of-Care Diagnostics market is projected to reach $75B by 2027 (markets & markets).
What Differentiates Us? Coagulation Sciences’ has the only platform that compares the ability of treatments to correct bleeding disorders. Results the clinician can use to support treatment decisions are available in ~ 10 minutes, at the Point-of-Care.
Intellectual Property: Patents have issued in major markets including the US (six unique patients), UK, Germany, Spain, France, Italy, Japan and China, with several pending.
Business Model: Profit margin on devices is projected to be 50%, while profit margin on single-use disposable cartridges is projected to exceed 70% translating to a razor and razor-blade business model.
Financial Projections: The company projects revenue in excess of $70M in year four of sales.
The Investment: CS is seeking to raise $2.16M to complete a $3M round ($840,000 has been invested to date). Two levels of warrant coverage will be provided; 25% for investments below $500,000, and 50% for investments of $500,000 and above.
Use of Funds: $800,000 Will permit the Company to hire a highly regarded healthcare investment bank to lead a follow-on Series A raise. An additional $1.36M to reach the $2.16M goal will fund salary support and additional clinical validation. The company has begun discussions with institutional investors. If Family Offices or Venture Capitalists invest in the near future, we may not require an Investment Bank.
Investor Traction: The company has received $5.8M in angel funding to date. After this round closes, with an Investment Bank leading a Series A raise, we plan to raise the capital needed to complete development and the clinical trial to support FDA clearance.
Investor requirements: Investors must be accredited, and the company is seeking investments of at least $100,000.
Meeting Agenda – September 28, 2023
5:30 pm - Arrival and networking, reception with wine, beer, and light fare provided by the wonderful Chef Tony Marciante. A kosher middle eastern option provided by Al Ha’esh of Rockville is available upon prior request.
6:30 pm - Company presentation with Q&A
7:45 pm - Coffee, dessert, networking
Location
Tysons Dulles Plaza - Conference Center
1420 Spring Hill Road
First Floor Conference Center
McLean, VA 22102
For more information, please e-mail Skylar Rallison at srallison@opus8.com
To request kosher option, please e-mail Avery North at anorth@opus8.com
You can register here on Eventbrite: https://CSPrivateDinner.eventbrite.com
NOTE: This Presentation / Reception is for Accredited Investors with the ability to invest $100,000 and Investor Representatives only.
We look forward to your participation.
The Opus8 Team